Factors influencing the quality and functioning of oncological multidisciplinary team meetings: results of a systematic review.

Decision making Education Evaluation Multidisciplinary team meeting Quality Team culture

Journal

BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677

Informations de publication

Date de publication:
27 Jun 2022
Historique:
received: 22 02 2022
accepted: 20 05 2022
entrez: 27 6 2022
pubmed: 28 6 2022
medline: 30 6 2022
Statut: epublish

Résumé

Discussing patients with cancer in a multidisciplinary team meeting (MDTM) is customary in cancer care worldwide and requires a significant investment in terms of funding and time. Efficient collaboration and communication between healthcare providers in all the specialisms involved is therefore crucial. However, evidence-based criteria that can guarantee high-quality functioning on the part of MDTMs are lacking. In this systematic review, we examine the factors influencing the MDTMs' efficiency, functioning and quality, and offer recommendations for improvement. Relevant studies were identified by searching Medline, EMBASE, and PsycINFO databases (01-01-1990 to 09-11-2021), using different descriptions of 'MDTM' and 'neoplasm' as search terms. Inclusion criteria were: quality of MDTM, functioning of MDTM, framework and execution of MDTM, decision-making process, education, patient advocacy, patient involvement and evaluation tools. Full text assessment was performed by two individual authors and checked by a third author. Seventy-four articles met the inclusion criteria and five themes were identified: 1) MDTM characteristics and logistics, 2) team culture, 3) decision making, 4) education, and 5) evaluation and data collection. The quality of MDTMs improves when the meeting is scheduled, structured, prepared and attended by all core members, guided by a qualified chairperson and supported by an administrator. An appropriate amount of time per case needs to be established and streamlining of cases (i.e. discussing a predefined selection of cases rather than discussing every case) might be a way to achieve this. Patient centeredness contributes to correct diagnosis and decision making. While physicians are cautious about patients participating in their own MDTM, the majority of patients report feeling better informed without experiencing increased anxiety. Attendance at MDTMs results in closer working relationships between physicians and provides some medico-legal protection. To ensure well-functioning MDTMs in the future, junior physicians should play a prominent role in the decision-making process. Several evaluation tools have been developed to assess the functioning of MDTMs. MDTMs would benefit from a more structured meeting, attendance of core members and especially the attending physician, streamlining of cases and structured evaluation. Patient centeredness, personal competences of MDTM participants and education are not given sufficient attention.

Sections du résumé

BACKGROUND BACKGROUND
Discussing patients with cancer in a multidisciplinary team meeting (MDTM) is customary in cancer care worldwide and requires a significant investment in terms of funding and time. Efficient collaboration and communication between healthcare providers in all the specialisms involved is therefore crucial. However, evidence-based criteria that can guarantee high-quality functioning on the part of MDTMs are lacking. In this systematic review, we examine the factors influencing the MDTMs' efficiency, functioning and quality, and offer recommendations for improvement.
METHODS METHODS
Relevant studies were identified by searching Medline, EMBASE, and PsycINFO databases (01-01-1990 to 09-11-2021), using different descriptions of 'MDTM' and 'neoplasm' as search terms. Inclusion criteria were: quality of MDTM, functioning of MDTM, framework and execution of MDTM, decision-making process, education, patient advocacy, patient involvement and evaluation tools. Full text assessment was performed by two individual authors and checked by a third author.
RESULTS RESULTS
Seventy-four articles met the inclusion criteria and five themes were identified: 1) MDTM characteristics and logistics, 2) team culture, 3) decision making, 4) education, and 5) evaluation and data collection. The quality of MDTMs improves when the meeting is scheduled, structured, prepared and attended by all core members, guided by a qualified chairperson and supported by an administrator. An appropriate amount of time per case needs to be established and streamlining of cases (i.e. discussing a predefined selection of cases rather than discussing every case) might be a way to achieve this. Patient centeredness contributes to correct diagnosis and decision making. While physicians are cautious about patients participating in their own MDTM, the majority of patients report feeling better informed without experiencing increased anxiety. Attendance at MDTMs results in closer working relationships between physicians and provides some medico-legal protection. To ensure well-functioning MDTMs in the future, junior physicians should play a prominent role in the decision-making process. Several evaluation tools have been developed to assess the functioning of MDTMs.
CONCLUSIONS CONCLUSIONS
MDTMs would benefit from a more structured meeting, attendance of core members and especially the attending physician, streamlining of cases and structured evaluation. Patient centeredness, personal competences of MDTM participants and education are not given sufficient attention.

Identifiants

pubmed: 35761282
doi: 10.1186/s12913-022-08112-0
pii: 10.1186/s12913-022-08112-0
pmc: PMC9238082
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

829

Informations de copyright

© 2022. The Author(s).

Références

Eur J Gen Pract. 2017 Dec;23(1):155-163
pubmed: 28554220
BMC Health Serv Res. 2020 Jun 24;20(1):579
pubmed: 32580714
Acta Otolaryngol. 2018 Feb;138(2):185-189
pubmed: 28978255
Eur J Cancer Care (Engl). 2019 Mar;28(2):e12971
pubmed: 30507003
BMJ Open. 2016 Jul 21;6(7):e012559
pubmed: 27443554
Breast. 2007 Apr;16(2):178-89
pubmed: 17158048
J Multidiscip Healthc. 2018 Jan 19;11:49-61
pubmed: 29403284
Eur J Cancer. 2008 Jul;44(10):1457-62
pubmed: 18325756
World J Surg Oncol. 2018 Jul 19;16(1):146
pubmed: 30025532
Cancer. 2007 Nov 1;110(9):1937-44
pubmed: 17823912
BMC Cancer. 2017 Nov 17;17(1):772
pubmed: 29149872
J Cancer Educ. 2008;23(4):235-7
pubmed: 19058072
Eur J Cancer. 2006 May;42(7):905-8
pubmed: 16516461
Ann Surg Oncol. 2011 Dec;18(13):3535-43
pubmed: 21594706
Oncol Res Treat. 2020;43(3):70-77
pubmed: 31743932
Cancer Med. 2020 Oct;9(19):7083-7099
pubmed: 32794351
Eur Radiol. 2021 Feb;31(2):983-991
pubmed: 32833089
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
PLoS One. 2019 Feb 15;14(2):e0212556
pubmed: 30768645
Aust Health Rev. 2017 Jul;41(3):291-296
pubmed: 27372543
BJU Int. 2021 Sep;128(3):271-279
pubmed: 34028162
Ann Surg Oncol. 2016 Aug;23(8):2430-7
pubmed: 27002814
Patient Educ Couns. 2021 Apr;104(4):792-799
pubmed: 33051128
BMC Health Serv Res. 2018 Jun 13;18(1):444
pubmed: 29898716
Australas Radiol. 2004 Dec;48(4):487-92
pubmed: 15601329
Colorectal Dis. 2009 Mar;11(3):291-5
pubmed: 18477019
J Eval Clin Pract. 2013 Dec;19(6):1035-43
pubmed: 23441961
Asia Pac J Clin Oncol. 2020 Feb;16(1):45-55
pubmed: 31721458
J Telemed Telecare. 2004;10(3):140-3
pubmed: 15237512
JCO Clin Cancer Inform. 2021 May;5:508-517
pubmed: 33974446
BMC Health Serv Res. 2018 Apr 5;18(1):249
pubmed: 29622020
BMC Health Serv Res. 2012 Dec 13;12:457
pubmed: 23237502
Intern Med J. 2017 May;47(5):529-535
pubmed: 28105750
Ann Surg Oncol. 2012 Jun;19(6):1759-65
pubmed: 22207050
Ann Surg Oncol. 2009 Oct;16(10):2731-7
pubmed: 19662458
BMC Health Serv Res. 2020 Jun 24;20(1):578
pubmed: 32580767
BMC Musculoskelet Disord. 2021 Jan 5;22(1):18
pubmed: 33402136
BMJ Open. 2012 Jun 25;2(3):
pubmed: 22734113
Int J Surg. 2013;11(5):389-94
pubmed: 23500030
Eur Ann Otorhinolaryngol Head Neck Dis. 2019 Apr;136(2):75-82
pubmed: 30503380
Ann Surg Oncol. 2013 May;20(5):1408-16
pubmed: 23086306
J Clin Neurosci. 2010 Sep;17(9):1130-5
pubmed: 20570520
J Oncol Pract. 2015 Jan;11(1):e66-74
pubmed: 25466708
BMC Cancer. 2012 May 29;12:202
pubmed: 22642614
Int J Qual Health Care. 2009 Apr;21(2):137-44
pubmed: 19147593
Ann Surg Oncol. 2016 Dec;23(13):4410-4417
pubmed: 27380047
Medicine (Baltimore). 2016 Jun;95(24):e3885
pubmed: 27310981
World J Surg. 2011 Sep;35(9):1970-6
pubmed: 21604049
Respirology. 2018 Oct;23(10):927-934
pubmed: 29641841
World J Surg. 2019 Feb;43(2):559-566
pubmed: 30382292
BMJ Open. 2017 Dec 28;7(12):e018629
pubmed: 29288182
Surg Endosc. 2014 Oct;28(10):2783-8
pubmed: 24879132
Ann Surg Oncol. 2012 Dec;19(13):4019-27
pubmed: 22820934
Eur J Cancer. 2007 Apr;43(6):1002-10
pubmed: 17329094
Int J Comput Assist Radiol Surg. 2018 Aug;13(8):1283-1290
pubmed: 29594852
Asia Pac J Clin Oncol. 2018 Feb;14(1):74-83
pubmed: 28949100
Qual Health Care. 2001 Jun;10(2):70-5
pubmed: 11389314
Lancet Oncol. 2005 Oct;6(10):738
pubmed: 16229093
BMC Health Serv Res. 2021 Mar 6;21(1):203
pubmed: 33676492
Ann Surg Oncol. 2013 Mar;20(3):715-22
pubmed: 23064794
BMJ Open Qual. 2019 Jun 4;8(2):e000631
pubmed: 31259288
J Oncol Pract. 2015 Sep;11(5):421-3
pubmed: 26384016
Br J Oral Maxillofac Surg. 2014 Feb;52(2):128-33
pubmed: 24280116
Cancer Med. 2021 Feb;10(4):1240-1252
pubmed: 33480191
Qual Health Res. 2015 Mar;25(3):397-407
pubmed: 25281239
J Urol. 2014 Sep;192(3):891-8
pubmed: 24631109
J Geriatr Oncol. 2019 Jan;10(1):74-83
pubmed: 30213454
Cancers (Basel). 2020 Apr 22;12(4):
pubmed: 32331449
Curr Oncol. 2021 Feb 23;28(1):1008-1016
pubmed: 33672110
Cancer Res Treat. 2017 Oct;49(4):1164-1169
pubmed: 28231425
J Oncol Pract. 2010 Nov;6(6):e17-20
pubmed: 21358945
Eur J Surg Oncol. 2004 Sep;30 Suppl 1:1-86
pubmed: 15358410
J Am Coll Surg. 2013 Sep;217(3):412-20
pubmed: 23891067
BMJ Open. 2019 Nov 7;9(11):e028609
pubmed: 31699717
Intern Med J. 2009 Dec;39(12):838-41
pubmed: 20233244
Eur J Oncol Nurs. 2019 Dec;43:101674
pubmed: 31689677
Am Soc Clin Oncol Educ Book. 2014;:e461-6
pubmed: 24857140
BMJ. 1995 Jun 3;310(6992):1425-6
pubmed: 7613269
Br J Hosp Med (Lond). 2020 Mar 2;81(3):1-6
pubmed: 32239992
Eur J Cancer. 2014 Feb;50(3):475-80
pubmed: 24321260
BMJ Open. 2019 May 27;9(5):e027303
pubmed: 31138582
Clin Transl Oncol. 2019 Oct;21(10):1319-1326
pubmed: 30721524
PLoS One. 2015 Oct 06;10(10):e0139921
pubmed: 26441328
Int J Qual Health Care. 2016 Jun;28(3):332-8
pubmed: 27084499
J Cancer Educ. 1996 Summer;11(2):84-8
pubmed: 8793648
Oncologist. 2014 Jun;19(6):654-60
pubmed: 24760711
J Neurooncol. 2017 May;133(1):1-7
pubmed: 28421461
Bull Cancer. 2020 Jul - Aug;107(7-8):730-737
pubmed: 32425210
J Multidiscip Healthc. 2014 Aug 11;7:355-63
pubmed: 25143743
BMJ Open Qual. 2019 May 31;8(2):e000435
pubmed: 31259279
Cancer Treat Rev. 2016 Jan;42:56-72
pubmed: 26643552

Auteurs

Janneke E W Walraven (JEW)

Department of Medical Oncology, Radboud University Medical Center, Postbus 9101, huispost 415, Nijmegen, 6500 HB, The Netherlands. janneke.walraven@radboudumc.nl.
Department of Research, Netherlands Comprehensive Cancer Organization, Goldebaldkwartier 419, Utrecht, 3511 DT, The Netherlands. janneke.walraven@radboudumc.nl.

Olga L van der Hel (OL)

Department of Research, Netherlands Comprehensive Cancer Organization, Goldebaldkwartier 419, Utrecht, 3511 DT, The Netherlands.

J J M van der Hoeven (JJM)

Department of Medical Oncology, Radboud University Medical Center, Postbus 9101, huispost 415, Nijmegen, 6500 HB, The Netherlands.

Valery E P P Lemmens (VEPP)

Department of Research, Netherlands Comprehensive Cancer Organization, Goldebaldkwartier 419, Utrecht, 3511 DT, The Netherlands.

Rob H A Verhoeven (RHA)

Department of Research, Netherlands Comprehensive Cancer Organization, Goldebaldkwartier 419, Utrecht, 3511 DT, The Netherlands.
Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Cancer Center AmsterdamMeibergdreef 9, Amsterdam, 1105 AZ, The Netherlands.

Ingrid M E Desar (IME)

Department of Medical Oncology, Radboud University Medical Center, Postbus 9101, huispost 415, Nijmegen, 6500 HB, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH